Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT04

Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Clinical Trials, Multiple Myeloma

Presenter: Jonathan L. Kaufman, MD, Associate Professor and Associate Vice-Chair, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

Co-Authors: Hareth Nahi, Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden; Saad Z. Usmani, Levine Cancer Institute/Atrium Health, Charlotte, NC; Maria-Victoria Mateos, University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; Niels W.C.J. van de Donk, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Philippe Moreau, Hematology, University Hospital Hôtel-Dieu, Nantes, France; Albert Oriol, Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain; Torben Plesner, Vejle Hospital and University of Southern Denmark, Vejle, Denmark; Shiyi Yang, Janssen Research & Development, Spring House, PA; Peter Hellemans, Janssen Research & Development, Beerse, Belgium; Brenda Tromp, Janssen Research & Development, Leiden, The Netherlands; Man (Melody) Luo, Janssen Research & Development, Raritan, NJ; Donna Zemlickis, Janssen Research & Development, Toronto, Ontario, Canada; Andrew Farnsworth, Janssen Research & Development, High Wycombe, United Kingdom; Ajai Chari, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

Background: Intravenous (IV) daratumumab is approved for the treatment of multiple myeloma. In the PAVO study Part 2, subcutaneous (SC) daratumumab, a coformulation of daratumumab and recombinant human hyaluronidase PH20 (rHuPH20), was well-tolerated, showed low infusion-related reaction (IRR) rates, consistent serum concentrations, and similar efficacy to IV daratumumab in relapsed or refractory multiple myeloma. This study represents Part 3 of the PAVO study.

Objective: To evaluate the safety of pre- and postdose corticosteroid tapering during SC daratumumab administration.

Methods: Relapsed or refractory multiple myeloma patients with ≥2 previous treatment lines received SC daratumumab (daratumumab 1800 mg plus rHuPH20 30,000 U in 15 mL) by manual SC injection per approved IV monotherapy dosing schedule. Patients received a 3-week tapering schedule (corticosteroid-free by cycle 1, day 22), with methylprednisolone given orally or intravenously predose (cycle 1, day 1, 100 mg; cycle 1, day 8, 60 mg; cycle 1, day 15, 30 mg) and orally postdose (cycle 1, day 1, 20 mg for 2 days; cycle 1, day 8, 20 mg for 1 day; cycle 1, day 15, 20 mg for 1 day), or a 2-week tapering schedule (corticosteroid-free by cycle 1, day 15), with methylprednisolone given orally or intravenously predose (cycle 1, day 1, 100 mg; cycle 1, day 8, 60 mg) and orally postdose (cycle 1, day 1, 20 mg for 2 days; cycle 1, day 8, 20 mg for 1 day).

Results: A total of 15 patients in each group received a median of 2 previous lines of therapy (range, 2-7), with 37% of patients having disease refractory to a proteasome inhibitor and an immunomodulatory drug. The 3-week and 2-week groups received a median of 14 (range, 2-22) and 12 (range, 3-19) SC daratumumab doses without corticosteroids, respectively. No IRRs were reported in the 3-week group. Three (20%) patients in the 2-week group had IRRs on cycle 1, day 1 (including grade 3 hypertension, grade 2 chills, grade 1 pyrexia, grade 1 oropharyngeal pain, and grade 1 tachycardia). IRRs occurred within 2 hours of the first administration; no IRRs were reported at later administrations. Most common (≥25%) treatment-emergent adverse events (AEs) in the 3-week and 2-week groups were upper respiratory tract infection (53% and 40%, respectively), nausea (47% and 20%, respectively), and fatigue (27% in each group). Most common (≥5%) grade 3 or 4 treatment-emergent AEs were neutropenia (0% and 20%, respectively), lymphopenia and hypertension (13% each and 0% each, respectively), and anemia (7% each). At a median follow-up of 7.7 months (in the 3-week group) and 5.6 months (in the 2-week group), the overall response rates were 40% each, and very good or better partial response rates were 13% and 27%, respectively.

Conclusion: Rapid corticosteroid tapering over 3 or 2 weeks is safe in patients with relapsed or refractory multiple myeloma receiving SC daratumumab. These data help guide future SC daratumumab combinations (ie, T-cell redirectors, CAR T-cell, or checkpoint inhibitors), where limiting concurrent corticosteroids may be preferred.

Related Items
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Multiple Myeloma
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.